Clinical Trial Update: A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM [Phase 1, Phase 2]

View source ↗

Summary

This terminated Phase 1/2 trial evaluated sonodynamic therapy using SONALA-001 in combination with the Exablate 4000 Type 2.0 device for recurrent glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Exablate 4000 Type 2.0
• SONALA-001

Snippet

Sponsor: SonALAsense, Inc. | Conditions: Recurrent GBM | Phase 1, Phase 2 | Status: TERMINATED